Results 101 to 110 of about 527 (122)

Mechanistic diversity within RLC-dependent myosin ATPase inhibitors differentiates EDG-7500, a diastolic-selective cardiac sarcomere modulator. [PDF]

JCI Insight
Emter CA, Henze M, DuVall M, Lehman S, Lee L, Barthel B, Hawryluk NA, Madden M, Wu Y, Perry A, Beyer M, Wei E, Rupert C, Roof S, Peter A, DiNatale E, Cantrell S, Tolley J, Schlachter S, van der Velden J, Michels M, Seidman C, Ma W, Leinwand L, Campbell S, Ochala J, Bluemke D, Tharp D, Seidman J, Del Rio CL, Semigran M, Evanchik M, Koch K, Russell A.   +33 more
europepmc   +1 more source

A New Era in the Management of Hypertrophic Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Perez-Asensio A, Llamas-Gomez H, Lara-Palomo A, Villar-Ruiz A, Jimenez-Mendez C, Palomino-Doza J.   +5 more
europepmc   +1 more source

Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM [PDF]

Circulation: Heart Failure
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality in children, but treatment options are limited. Aficamten, a next-in-class cardiac myosin inhibitor, directly targets the hypercontractility underlying HCM ...
Stephanie J Nakano, Paul F Kantor, Fady I Malik   +2 more
exaly   +4 more sources

Effect of Aficamten on Cardiac Structure and Function in Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. [PDF]

Circulation
BACKGROUND: Aficamten significantly improved both functional capacity and patient-reported health status in patients with symptomatic nonobstructive hypertrophic cardiomyopathy in the phase 3 randomized, placebo ...
Mathew S Maurer, Estêvão Lanna Figueiredo, Edileide de Barros Correia   +2 more
exaly   +3 more sources

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American College of Cardiology, 2023
Background: Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM).
Albree Tower-Rader, Timothy Wong, Caroline J Coats   +2 more
exaly   +2 more sources

Efficacy of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms: Results From the SEQUOIA-HCM Trial [PDF]

European Heart Journal
Background and Aims: Patients with obstructive hypertrophic cardiomyopathy (oHCM) treated with aficamten in SEQUOIA-HCM (NCT05186818) demonstrated marked improvement in symptoms and functional capacity.
Albree Tower-Rader, Michael E Nassif, Sherif F Nagueh   +2 more
exaly   +3 more sources

Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM [PDF]

Journal of the American College of Cardiology
Background: Aficamten is a cardiac myosin inhibitor that mitigates left ventricular outflow gradients in obstructive hypertrophic cardiomyopathy (oHCM).
Matthew Lee, Michael E Nassif, Pablo Garcia-Pavia   +2 more
exaly   +3 more sources

Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM [PDF]

Journal of the American College of Cardiology
A primary goal in treating obstructive hypertrophic cardiomyopathy (oHCM) is to improve patients' health status: their symptoms, function, and quality of life.
Michael E Nassif, Pablo Garcia-Pavia, Lisa Meng   +2 more
exaly   +2 more sources